These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 10794089)

  • 1. A safer plasma supply from remunerated donors--"The Immuno/Community Bio-Resources experiment".
    Waytes AT; Igel H; Zerlauth G; Wappler N; Lee M; Schwarz O
    Dev Biol (Basel); 2000; 102():37-51. PubMed ID: 10794089
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reducing the risk of infection from plasma products: specific preventative strategies.
    Burnouf T; Radosevich M
    Blood Rev; 2000 Jun; 14(2):94-110. PubMed ID: 11012252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Requirements for testing human blood donors for evidence of infection due to communicable disease agents. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2001 Jun; 66(112):31146-65. PubMed ID: 11725786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of nucleic acid testing for hepatitis B virus, hepatitis C virus, and human immunodeficiency virus on the safety of blood supply in Italy: a 6-year survey.
    Velati C; Romanò L; Fomiatti L; Baruffi L; Zanetti AR;
    Transfusion; 2008 Oct; 48(10):2205-13. PubMed ID: 18631163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Collection of source material from remunerated donors.
    Rodell MB
    Dev Biol Stand; 1993; 81():57-64. PubMed ID: 8174821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Experience of German Red Cross blood donor services with nucleic acid testing: results of screening more than 30 million blood donations for human immunodeficiency virus-1, hepatitis C virus, and hepatitis B virus.
    Hourfar MK; Jork C; Schottstedt V; Weber-Schehl M; Brixner V; Busch MP; Geusendam G; Gubbe K; Mahnhardt C; Mayr-Wohlfart U; Pichl L; Roth WK; Schmidt M; Seifried E; Wright DJ;
    Transfusion; 2008 Aug; 48(8):1558-66. PubMed ID: 18466173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Do patient-related blood donors represent a threat to the safety of the blood supply?
    Pereira A; Sanz C; Tàssies D; Ramírez B
    Haematologica; 2002 Apr; 87(4):427-33. PubMed ID: 11940488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predonation screening of blood donors with rapid tests: implementation and efficacy of a novel approach to blood safety in resource-poor settings.
    Owusu-Ofori S; Temple J; Sarkodie F; Anokwa M; Candotti D; Allain JP
    Transfusion; 2005 Feb; 45(2):133-40. PubMed ID: 15660820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Should HBV DNA NAT replace HBsAg and/or anti-HBc screening of blood donors?
    Busch MP
    Transfus Clin Biol; 2004 Feb; 11(1):26-32. PubMed ID: 14980546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Residual infectious disease risk in screened blood transfusion from a high-prevalence population: Santa Catarina, Brazil.
    Maresch C; Schluter PJ; Wilson AD; Sleigh A
    Transfusion; 2008 Feb; 48(2):273-81. PubMed ID: 18005323
    [TBL] [Abstract][Full Text] [Related]  

  • 11. NAT and viral safety in blood transfusion.
    Roth WK; Buhr S; Drosten C; Seifried E
    Vox Sang; 2000; 78 Suppl 2():257-9. PubMed ID: 10938964
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detection of HCV and HIV-1 antibody negative infections in Scottish and Northern Ireland blood donations by nucleic acid amplification testing.
    Jarvis LM; Dow BC; Cleland A; Davidson F; Lycett C; Morris K; Webb B; Jordan A; Petrik J
    Vox Sang; 2005 Oct; 89(3):128-34. PubMed ID: 16146504
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nucleic acid amplification technology screening for hepatitis C virus and human immunodeficiency virus for blood donations.
    Bamaga MS; Bokhari FF; Aboud AM; Al-Malki M; Alenzi FQ
    Saudi Med J; 2006 Jun; 27(6):781-7. PubMed ID: 16758035
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of viral nucleic acid testing on contamination frequency of manufacturing plasma pools.
    Nübling CM; Unkelbach U; Chudy M; Seitz R
    Transfusion; 2008 May; 48(5):822-6. PubMed ID: 18208414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-remunerated donations.
    Leikola J
    Dev Biol Stand; 1993; 81():51-6. PubMed ID: 8174820
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Community blood supply model: development of a new model to assess the safety, sufficiency, and cost of the blood supply.
    Custer B; Johnson ES; Sullivan SD; Hazlet TK; Ramsey SD; Murphy EL; Busch MP
    Med Decis Making; 2005; 25(5):571-82. PubMed ID: 16160212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A pilot study for screening blood donors in Taiwan by nucleic acid amplification technology: detecting occult hepatitis B virus infections and closing the serologic window period for hepatitis C virus.
    Li L; Chen PJ; Chen MH; Chak KF; Lin KS; Tsai SJ
    Transfusion; 2008 Jun; 48(6):1198-206. PubMed ID: 18422856
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of individual-donation nucleic acid testing on risk of human immunodeficiency virus, hepatitis B virus, and hepatitis C virus transmission by blood transfusion in South Africa.
    Vermeulen M; Lelie N; Sykes W; Crookes R; Swanevelder J; Gaggia L; Le Roux M; Kuun E; Gulube S; Reddy R
    Transfusion; 2009 Jun; 49(6):1115-25. PubMed ID: 19309474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis C virus transmission through quarantine fresh-frozen plasma.
    Humpe A; Legler TJ; Nübling CM; Riggert J; Unger G; Wolf C; Heermann KH; Köhler M
    Thromb Haemost; 2000 Nov; 84(5):784-8. PubMed ID: 11127856
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Limited effectiveness of donor deferral registries for transfusion-transmitted disease markers.
    Cable R; Musavi F; Notari E; Zou S;
    Transfusion; 2008 Jan; 48(1):34-42. PubMed ID: 17894796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.